Cummings SR, Melton LJI. Epidemiology and outcomes of osteoporotic fractures. Lancet.2002;359:1761-1767.
Not Available. NIH consensus declares osteoporosis a major public health issue. Osteoporosis Rep.2000;16:1.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women's Health Initiative randomized controlled
Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res.2000;15:183-187.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ.1996;312:1254-1259.
Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes
in bone density. J Clin Endocrinol Metab.2000;85:231-236.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence
of nonvertebral fractures that occur during treatment with antiresorptive
agents. J Clin Endocrinol Metab.2002;87:1586-1592.
Cummings SR, Karpf DB, Harris F.
et al. Improvement in spine bone density and reduction in risk of vertebral
fractures during treatment with antiresorptive drugs. Am J Med.2002;112:281-289.
Bone HG, Greenspan SL, McKeever C.
et al. Alendronate and estrogen effects in postmenopausal women with low bone
mineral density. J Clin Endocrinol Metab.2000;85:720-726.
Looker AC, Johnston Jr CC, Wahner HW.
et al. Prevalence of low femoral bone density in older US women from NHANES
III. J Bone Miner Res.1995;10:796-802.
Dawson-Hughes B, Jacques P, Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal
women. Am J Clin Nutr.1987;46:685-687.
Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do elderly women discontinue hormone replacement therapy? J Womens Health Gender Based Med.2001;10:343-350.
Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age: a longitudinal study in women
over age 65. J Bone Miner Res.1994;9:1959-1965.
Greenspan SL, Maitland-Ramsey L, Myers E. Classification of osteoporosis in the elderly is dependent on site-specific
analysis. Calcif Tissue Int.1996;58:409-414.
Lu Y, Mathur AK, Blunt BA.
et al. Dual X-ray absorptiometry quality control: comparison of visual examination
and process-control charts. J Bone Miner Res.1996;11:626-637.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities
of daily living. Gerontologist.1969;9:179-186.
Folstein MF, Folstein SE, McHugh PR. Mini mental state. J Psychiatr Res.1975;12:189-198.
Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term
response to alendronate therapy in representative elderly women: a randomized
clinical trial. J Bone Miner Res.1998;13:1431-1438.
Greendale GA, Wells B, Marcus R, Barrett-Connor E.for the Postmenopausal Estrogen/Progestin Interventions Trial Investigators. How many women lose bone mineral density while taking hormone replacement
therapy? results from the Postmenopausal Eastrogen/Progestin Interventions
trial. Arch Intern Med.2000;160:3065-3071.
Kanis JA, Melton LJ, Christiansen III C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res.1994;9:1137-1141.
Kanis JA.for the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal
osteoporosis: synopsis of a WHO report. Osteoporos Int.1994;4:368-381.
Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease
risk factors in postmenopausal women. JAMA.1995;273:199-208.
Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly
women: a randomized controlled trial. JAMA.2001;286:815-820.
Black DM, Cummings SR, Karpf DB.
et al. Randomised trial of effect of alendronate on risk of fracture in women
with existing vertebral fractures. Lancet.1996;348:1535-1541.
Cummings SR, Black DM, Thompson DE.
et al. Effect of alendronate on risk of fracture in women with low bone density
but without vertebral fractures: results from the Fracture Intervention Trial. JAMA.1998;280:2077-2082.
Ettinger B, Black DM, Mitlak BH.
et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: results from a 3-year randomized clinical trial. JAMA.1999;282:637-645.
Harris ST, Watts NB, Genant HK.
et al. Effects of risedronate treatment on vertebral and nonvertebral fractures
in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA.1999;282:1344-1352.
Reginster J-Y, Minne HW, Sorensen OH.
et al. Randomized trial of the effects of risedronate on vertebral fractures
in women with established postmenopausal osteoporosis. Osteoporos Int.2000;11:83-91.
Palomba S, Orio FJ, Colao A.
et al. Effect of estrogen replacement plus low-dose alendronate treatment
on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab.2002;87:1502-1508.
Harris S, Eriksen EF, Davidson M.
et al. Effects of combined risedronate and hormone replacement therapies on
bone mineral density in postmenopausal women. J Clin Endocrinol Metab.2002;86:1890-1897.
Liberman UA, Weiss SR, Broll J.
et al. Effect of oral alendronate on bone mineral density and the incidence
of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis
Treatment Study Group. N Engl J Med.1995;333:1437-1443.
Hulley S, Grady D, Buch T.
et al. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA.1996;276:1389-1396.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA.2002;288:872-881.
Hulley S, Furberg C, Barrett-Connor E.
et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA.2002;288:58-66.
Grady D, Herrington D, Bittner V.
et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA.2002;288:49-57.
Kanaya AM, Herrington D, Vittinghoff E.
et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin
Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med.2003;138:1-9.
Wilson PWF. Lower diabetes risk with hormone replacement therapy: an encore for
estrogen? Ann Intern Med.2003;138:69-70.
LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: a systematic review and
Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA.for the HERS Research Group. Quality-of-life and depressive symptoms in postmenopausal women after
receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement
Study (HERS) trial. JAMA.2002;287:591-597.
Kuchel GA, Tannenbaum C, Greenspan SL, Resnick NM. Can variability in the hormonal status of elderly women assist in the
decision to administer estrogens? J Womens Health Gender Based Med.2001;10:109-116.